Innovating the Pink Eye Treatment Landscape

Leading candidate in Phase 2B for the treatment of Acute Infectious Conjunctivitis.

Enhancing Lives Through Better Vision

Okogen is a clinical stage ophthalmic pharmaceutical company. Our lead product is in clinical trials as a “one stop shop” treatment for all forms of acute infectious conjunctivitis, including bacterial and viral.

Pink eye (conjunctivitis) is when the conjunctiva is irritated by a viral or bacterial infection or allergies. Bacterial and viral conjunctivitis are easily spread from person to person.

– American Academy of Ophthalmology

The current conjunctivitis market is USD $4.2 billion annually and is estimated to reach $6.1 billion by 2031.
85% of this market is driven by antibiotics that are prescribed regardless of etiology of infection
Infectious conjunctivitis represents ~60% of the total conjunctivitis market and 1-2% of all primary care visits worldwide
There are currently no approved treatments for adenoviral conjunctivitis, comprising +90% of all viral ocular infections
Okogen is pursuing a comprehensive treatment for both bacterial and viral conjunctivitis

Latest News & Press

View All News

Press Release

Okogen, Inc., Announces Initiation of Phase IIb Clinical Trial for Pink Eye (Acute Infectious Conjunctivitis)

October 31, 2023

Press Release

Okogen, Inc., Announces Ophthalmology Industry Veteran Joshua Moriarty as New Chief Executive Officer

March 8, 2022

Press Release

Safe, Effective and Dose Responsive Anti-Viral Activity of OKG-0301 in Patients with Acute Adenoviral Conjunctivitis–Phase 2 Interim Analysis Results from RUBY Clinical Trial

April 29, 2021